INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 06, 2019 09:41 ET
|
Schall Law
LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
July 31, 2019 09:35 ET
|
Schall Law
LOS ANGELES, July 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc...
Mallinckrodt Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
May 21, 2019 15:13 ET
|
Block & Leviton LLP
BOSTON, May 21, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Mallinckrodt PLC (NYSE: MNK) and certain of its...
Mallinckrodt Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
May 01, 2019 12:58 ET
|
Block & Leviton LLP
BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Mallinckrodt PLC (“Mallinckrodt” or the...
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
August 15, 2018 09:26 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
July 30, 2018 07:55 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
June 01, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction...
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
May 23, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
November 02, 2017 06:56 ET
|
Ocera Therapeutics, Inc.
-- Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right -- -- Hepatic encephalopathy (HE) is a neuropsychiatric syndrome...
MNK ALERT: Rosen Law Firm Reminds Mallinckrodt Public Limited Company Investors of Important Deadline in Class Action – MNK
March 10, 2017 15:51 ET
|
The Rosen Law Firm PA
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Mallinckrodt Public Limited Company securities (NYSE:MNK) from November 25, 2014...